| Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations H Andrikovics, T Krahling, K Balassa, G Halm, A Bors, M Koszarska, ... haematologica 99 (7), 1184, 2014 | 144 | 2014 |
| Molecular diagnostics of myeloproliferative neoplasms SE Langabeer, H Andrikovics, J Asp, B Bellosillo, S Carillo, K Haslam, ... European journal of haematology 95 (4), 270-279, 2015 | 103 | 2015 |
| Analysis of large structural changes of the factor VIII gene, involving intron 1 and 22, in severe hemophilia A H Andrikovics, I Klein, A Bors, L Nemes, A Marosi, A Váradi, A Tordai haematologica 88 (7), 778-784, 2003 | 99 | 2003 |
| A certified plasmid reference material for the standardisation of BCR–ABL1 mRNA quantification by real-time quantitative PCR H White, L Deprez, P Corbisier, V Hall, F Lin, S Mazoua, S Trapmann, ... Leukemia 29 (2), 369-376, 2015 | 96 | 2015 |
| Isoform-specific up-regulation of plasma membrane Ca2+ ATPase expression during colon and gastric cancer cell differentiation P Ribiczey, A Tordai, H Andrikovics, AG Filoteo, JT Penniston, J Enouf, ... Cell calcium 42 (6), 590-605, 2007 | 83 | 2007 |
| ATG16L1 and IL23 receptor (IL23R) genes are associated with disease susceptibility in Hungarian CD patients PL Lakatos, T Szamosi, A Szilvasi, E Molnar, L Lakatos, A Kovacs, ... Digestive and liver disease 40 (11), 867, 2008 | 76 | 2008 |
| Decreased frequencies of ABCA1 polymorphisms R219K and V771M in Hungarian patients with cerebrovascular and cardiovascular diseases H Andrikovics, E Pongrácz, Ð Kalina, A Szilvási, C Aslanidis, G Schmitz, ... Cerebrovascular Diseases 21 (4), 254-259, 2006 | 73 | 2006 |
| Association of some rare haplotypes and genotype combinations in the< i> MDR1</i> gene with childhood acute lymphoblastic leukaemia ÁF Semsei, DJ Erdélyi, I Ungvári, E Kámory, B Csókay, H Andrikovics, ... Leukemia research 32 (8), 1214-1220, 2008 | 68 | 2008 |
| The R1141X loss-of-function mutation of the ABCC6 gene is a strong genetic risk factor for coronary artery disease G Köblös, H Andrikovics, Z Prohászka, A Tordai, A Váradi, T Arányi Genetic Testing and Molecular Biomarkers 14 (1), 75-78, 2010 | 67 | 2010 |
| Synergistic interaction of ABCB1 and ABCG2 polymorphisms predicts the prevalence of toxic encephalopathy during anticancer chemotherapy DJ Erdιlyi, E Kamory, B Csokay, H Andrikovics, A Tordai, C Kiss, ... The pharmacogenomics journal 8 (5), 321-327, 2008 | 65 | 2008 |
| Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale NCP Cross, HE White, T Ernst, L Welden, C Dietz, G Saglio, FX Mahon, ... Leukemia 30 (9), 1844-1852, 2016 | 58 | 2016 |
| The role of the human ABCG2 multidrug transporter and its variants in cancer therapy and toxicology J Cervenak, H Andrikovics, C Özvegy-Laczka, A Tordai, K Német, ... Cancer letters 234 (1), 62-72, 2006 | 57 | 2006 |
| High incidence of hemochromatosis gene mutations in the myelodysplastic syndrome: the Budapest Study on 50 patients J Várkonyi, G Tarkovács, I Karádi, H Andrikovics, F Varga, J Demeter, ... Acta haematologica 109 (2), 64-67, 2003 | 56 | 2003 |
| Expression levels of the ABCG2 multidrug transporter in human erythrocytes correspond to pharmacologically relevant genetic variations I Kasza, G Várady, H Andrikovics, M Koszarska, A Tordai, GL Scheffer, ... PLoS One 7 (11), e48423, 2012 | 50 | 2012 |
| ATP-binding cassette transporter ABCG2 (BCRP) and ABCB1 (MDR1) variants are not associated with disease susceptibility, disease phenotype response to medical therapy or need … S Fischer, PL Lakatos, Hungarian IBD Study Group, L Lakatos, A Kovacs, ... Scandinavian journal of gastroenterology 42 (6), 726-733, 2007 | 50 | 2007 |
| Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia M Koszarska, A Bors, A Feczko, N Meggyesi, A Batai, J Csomor, E Adam, ... Leukemia & lymphoma 54 (5), 1028-1035, 2013 | 47 | 2013 |
| Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia … N Meggyesi, A Kozma, G Halm, S Nahajevszky, Á Bátai, S Fekete, A Barta, ... Acta Haematologica 127 (1), 34-42, 2012 | 43 | 2012 |
| First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR–ABL transcripts H Andrikovics, S Nahajevszky, A Szilvási, A Bors, E Adám, A Kozma, ... Hematological oncology 25 (3), 143-147, 2007 | 39 | 2007 |
| The role of ABC-transporter gene polymorphisms in chemotherapy induced immunosuppression, a retrospective study in childhood acute lymphoblastic leukaemia DJ Erdélyi, E Kámory, A Zalka, ÁF Semsei, B Csókay, H Andrikovics, ... Cellular immunology 244 (2), 121-124, 2006 | 39 | 2006 |
| JAK2 46/1 haplotype analysis in myeloproliferative neoplasms and acute myeloid leukemia H Andrikovics, S Nahajevszky, M Koszarska, N Meggyesi, A Bors, G Halm, ... Leukemia 24 (10), 1809-1813, 2010 | 38 | 2010 |
